




FIG. 1










FIG. 2A




24 Hours



8 Hours



2 Hours



DUSP4

DUSP6

SPRY2

FIG. 2B




FIG. 2C




FIG. 2D




FIG. 2E




FIG. 2F




FIG. 2G




FIG. 2H










FIG. 2I




24 Hours



8 Hours



2 Hours



Axin2

CTGF

AREG

FIG. 3A




FIG. 3B




FIG. 3C




FIG. 3D





FIG. 3E

## HOP62 (WSLC)

Karpas-299 (Lymphoma)

Lox-1/11 (Melanoma)

1990-1991



**FIG. 4A**

## Cell surface PD-L1 (FACS)




FIG. 4B




FIG. 5B




FIG. 5A




FIG. 5C




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10A




FIG. 10B




FIG.11

### DUSP6 mRNA

$^{***} = p < 0.01$ ,  $^{****} = p < 0.001$ ,  $^{*****} = p < 0.0001$




FIG. 12A

### AXIN2 mRNA

$^{*} = p < 0.05$ ,  $^{****} = p < 0.0001$




FIG. 12C

### cMyc mRNA

$^{***} = p < 0.001$ ,  $^{****} = p < 0.0001$




FIG. 12B

### AREG mRNA

$^{*} = p < 0.05$ ,  $^{***} = p < 0.001$ ,  $^{****} = p < 0.0001$




FIG. 12D


**DUSP4 mRNA**

FIG. 13A


**SPRY2 mRNA**

FIG. 13B


**CCND1 mRNA**

FIG. 13C


**YAP Protein**

FIG. 13D




FIG. 14A




FIG. 14B




FIG. 14C






FIG. 14D






FIG. 16




FIG. 17




FIG. 18




FIG. 19B




FIG. 19A




FIG. 19D




FIG. 19C




FIG. 19E




FIG. 20


**2 hr****8 hr****24 hr**

FIG. 21A



**2 hr****8 hr****24 hr**

FIG. 21B



**Human Bronchial Epithelial cell gene expression at 24hrs**

FIG. 22

|                            |
|----------------------------|
| SW48 (CRC b-catenin, EGFR) |
|----------------------------|

| <u>MEKi (Tra)</u> | Compound 1 | GDC0994 | uM |
|-------------------|------------|---------|----|
|-------------------|------------|---------|----|




FIG. 23A

|                                       |
|---------------------------------------|
| HCT-116 (CRC b-catenin, KRAS, PIK3CA) |
|---------------------------------------|

| MEKi (Tra) | Compound 1 | GDC0994 | uM |
|------------|------------|---------|----|
|------------|------------|---------|----|




FIG. 23B

|                               |
|-------------------------------|
| AGS (Gastric b-catenin, KRAS) |
|-------------------------------|




FIG. 23C

# Hep3B (HCC b-catenin active)




FIG. 23D

AGS resistant to trametinib




FIG. 24




FIG. 25